dr. rini on the axitinib and sorafenib trial vegf focus
Published 13 years ago • 137 plays • Length 0:44Download video MP4
Download video MP3
Similar videos
-
0:43
dr. rini on the results from his axitinib and sorafenib trial
-
0:43
dr. rini discusses the vegf targeted agent axitinib
-
1:12
dr. rini describes axitinib's and sorafenib's side effects
-
0:38
dr. rini explains the axitinib integration process
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
26:06
kidney cancer | dr. tony talebi discusses the treatment of stage 4 metastatic renal cell carcinoma
-
1:19
dr. rini on the efficacy of axitinib and pembrolizumab in rcc
-
1:34
dr. rini on pembrolizumab plus axitinib in rcc
-
1:20
dr. cella on the side effect focus of the axitinib and sorafenib trial
-
2:16
axitinib showed two-month advantage to sorafenib
-
1:03
dr. rini on managing the toxicity of pembrolizumab plus axitinib in mrcc
-
1:19
dr. nicholas vogelzang on first-line axitinib versus sorafenib in mrcc
-
0:53
dr. rini on standards of care for advanced rcc
-
11:26
axis trial: second-line axitinib versus sorafenib in metastatic renal cell carcinoma
-
9:52
phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
-
2:11
dr. cella discusses axitinib and sorafenib axis trial
-
3:57
agile trial: frontline axitinib versus sorafenib in metastatic renal cell carcinoma
-
3:18
phase 3 axis 1032 trial discussion with brian i. rini, md
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
0:43
dr. rini on adjuvant immunotherapy in renal cell carcinoma